Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04547777 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

A Phase 1 study of Glioma, Malignant, sponsored by Darell Bigner.

Recruiting
Registry status
Phase 1
Development phase
90
Enrollment target
1
Study location

NCT04547777 is a Phase 1 study of Glioma, Malignant that is actively recruiting participants, run by Darell Bigner. The registered enrollment target is 90 participants, above the 59-participant average among 19 other Glioma, Malignant trials with a reported enrollment target (53% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04547777, a Phase 1 study of Glioma, Malignant, is actively recruiting participants, sponsored by Darell Bigner.

RECRUITING
Registry status
Phase 1
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

This is a phase 1 study of an anti-CD40 monoclonal antibody (2141-V11) in combination with D2C7-IT for patients with recurrent World Health Organization (WHO) grade III or IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.

Conditions Studied

Glioma, Malignant

Interventions

  • DRUG D2C7-IT
  • DRUG 2141-V11

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2021-07-09
Est. Completion 2027-06
Phase Phase 1

Sponsor

Darell Bigner

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04547777

The ClinicalTrials.gov registry entry for NCT04547777 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 59-participant average among 19 other Glioma, Malignant trials with a reported enrollment target (53% higher). The listed sponsor is Darell Bigner, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glioma, Malignant appearing as the primary indexed condition, and to 2 interventions - of which D2C7-IT is the first listed.

NCT04547777 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT04547777 about?

NCT04547777 is a clinical study titled "Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma". This is a phase 1 study of an anti-CD40 monoclonal antibody (2141-V11) in combination with D2C7-IT for patients with recurrent World Health Organization (WHO) grade III or IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.

What is the current status of trial NCT04547777?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2021-07-09. Estimated completion is 2027-06.

What conditions does trial NCT04547777 study?

This clinical trial studies the following conditions: Glioma, Malignant.

What interventions are being tested in trial NCT04547777?

The interventions under investigation include: D2C7-IT (DRUG), 2141-V11 (DRUG).

Who is sponsoring clinical trial NCT04547777?

This trial is sponsored by Darell Bigner, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04547777 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioma, Malignant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioma, Malignant

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.